BEIJING, May 18, 2018 /PRNewswire/ — Shineco, Inc. (“Shineco” or the “Company”; NASDAQ: TYHT), a producer and distributor of Chinese herbal medicines, organic agricultural produce, specialized textiles, and other health and well-being focused plant-based products in China, announced today its financial results for the third quarter ended March 31, 2018.

Mr. Yuying Zhang, Chairman and Chief Executive Officer of Shineco, Inc., commented, “We are delighted that our increased capital spending in 2017 has translated into increased profitability in 2018. Our business in Xinjiang factory has turned a profit, and our sales in Shandong have remained stable. This is reflected in our financial results. Shineco’s gross profit had increased by 102% to $5.26 million, our operating margin had increased by 8.4 percentage points to 29.4%, and our gross margin had increased by 6.7 percentage points to 39.4% compared to the same period of last year.”

Mr. Zhang concluded, “The market’s response to our Luobuma product line has been immensely positive, as reflected by an impressive sales increase of 388.6% to $5.48 million from $1.12 million from the same period of last year. We are pleased with the recognition from our clients, as we continue to innovate and expand in the future.”

Third Quarter of 2018 Financial Highlights

• Revenues increased by 68.0% to $13.34 million for the three months ended March 31, 2018 from $7.94 million for the same period last year.
• Gross profit increased by 102.2% to $5.26 million for the three months ended March 31, 2018 from $2.60 million for the same period last year. Gross margin increased by 6.7 percentage points to 39.4% from 32.8% for the same period of last year.
• Net income attributable to Shineco increased by 136.8% to $4.55 million, or $0.21 per basic and diluted share, for the three months ended March 31, 2018 from $1.92 million, or $0.09 per basic and diluted share, for the same period last year. The increases in net income and earnings per share were primarily due to an increase in gross profit, partially offset by an increase in general and administrative expenses.

Third Quarter of 2018 Financial Results

Revenues

Revenues for the three months ended March 31, 2018 increased by $5.40 million, or 68.0%, to $13.34 million from $7.94 million for the same period of last year, mainly due to increased sales of all products.

Revenues from Luobuma products increased by $4.36 million, or 388.6%, to $5.48 million for the three months ended March 31, 2018 from $1.12 million for the same period of last year, mainly due to establishment of new subsidiary, Xinjiang Taihe, which generated revenue of $5,210,768.

Revenues from Chinese medicinal herbal products increased by $0.25 million, or 8.3%, to $3.30 million for the three months ended March 31, 2018 from $3.05 million for the same period of last year. The increase was primarily due to more fulfilled sales orders from customers for the three months ended March 31, 2018 than the same period in 2017.

Revenues from other agricultural products increased by $0.79 million, or 20.9%, to $4.56 million for the three months ended March 31, 2018 from $3.77 million for the same period of last year. The sales of other agricultural products were mainly derived from sales of yew trees and our storage services. The increase was mainly due to the increase in sales volume of yew trees since the public realized the air purification function of the yew trees.

Gross profit and Gross Margin

Total cost of goods sold increased by $2.74 million, or 51.3%, to $8.08 million for the three months ended March 31, 2018 from $5.34 million for the same period of last year. Gross profit increased by $2.66 million, or 102.2%, to $5.26 million for the three months ended March 31, 2018 from $2.60 million for the same period of last year. Overall gross margin increased by 6.7 percentage points to 39.4% for the three months ended March 31, 2018, compared to 32.8% for the same period of last year.

Gross margins for Luobuma products, Chinese medicinal herbal products, and other agricultural products were 56.9%, 22.0%, and 31.0%, respectively, for the three months ended March 31, 2018. This compared to gross margins for Luobuma products, Chinese medicinal herbal products, and other agricultural products of 49.2%, 24.7%, and 34.4%, respectively, for the same period of last year.

Operating income

Selling expenses increased by $0.08 million, or 27.4%, to $0.39 million for the three months ended March 31, 2018 from $0.30 million for the same period of last year, primarily due to the acquisition of a new subsidiary, Tianjin Tajite, in October 2017. The increase in selling and distribution expenses was also a result of increased promotion expenses as the Company enhanced its online sales promotions, partially offset by decreased rent expense of warehouse and salary expenses due to more effective cost control during the three months ended March 31, 2018 compared to the same period of 2017. General and administrative expenses increased by $0.33 million, or 51.5%, to $0.96 million for the three months ended March 31, 2018 from $0.63 million for the same period of last year. The increase in general and administrative expenses was primarily due to the incorporation and acquisition of new subsidiaries, Tiankunrunze in last quarter of fiscal year 2017, and Xinjiang Taihe and Tianjin Tajite in fiscal year 2018. As a result, total operating expenses increased by $0.41 million, or 43.6%, to $1.34 million for the three months ended March 31, 2018 from $0.94 million for the same period of last year.

Operating income increased by $2.25 million, or 135.0%, to $3.92 million for the three months ended March 31, 2018 from $1.67 million for the same period of last year. Operating margin was 29.4% for the three months ended March 31, 2018, compared to 21.0% for the same period of last year.

Net income

Net income increased by $2.55 million, or 130.4%, to $4.51 million for the three months ended March 31, 2018 from $1.96 million for the same period of last year. After the deduction of non-controlling interests, net income attributable to common shareholders for the three months ended March 31, 2018 was $4.55 million, or $0.21 per basic and diluted share. This compared to net income attributable to common shareholders of $1.92 million, $0.09 per basic and diluted share, for the same period of last year.

Nine Months Ended March 31, 2018 Financial Results

Revenues

Revenues for the nine months ended March 31, 2018 increased by $9.75 million, or 38.2%, to $35.28 million from $25.53 million for the same period of last year, mainly due to increased sales of all products. 

Revenues from Luobuma products increased by $7.64 million, or 276.0%, to $10.41 million for the nine months ended March 31, 2018 from $2.77 million for the same period of last year, mainly due to revenue generated by a new subsidiary, Xinjiang Taihe, of US$ 8,145,196. Moreover, the increase of revenue from this segment was due to increased sales volume of our health awareness related products. The Company also enhanced online sales promotions during the nine months ended March 31, 2018, which contributed to more sales revenue overall.

Revenues from Chinese medicinal herbal products increased by $0.51 million, or 5.2%, to $10.23 million for the nine months ended March 31, 2018 from $9.73 million for the same period of last year. The increase was primarily due to more fulfilled sales orders from customers for the nine months ended March 31, 2018 than the same period in 2017.

Revenues from other agricultural products increased by $1.60 million, or 12.3%, to $14.64 million for the nine months ended March 31, 2018 from $13.04 million for the same period of last year. The increase was mainly attributable to the increase in sales volume of yew trees since the public realized the air purification function of the yew trees.

Gross profit and Gross Margin

Total cost of goods sold increased by $6.06 million, or 35.5%, to $23.11 million for the nine months ended March 31, 2018 from $17.06 million for the same period of last year. Gross profit increased by $3.70 million, or 43.6%, to $12.17 million for the nine months ended March 31, 2018 from $8.47 million for the same period of last year. Overall gross margin increased by 1.3 percentage points to 34.5% for the nine months ended March 31, 2018, compared to 33.2% for the same period of last year.

Gross margins for Luobuma products, Chinese medicinal herbal products, and other agricultural products were 53.7%, 22.5%, and 29.2%, respectively, for the nine months ended March 31, 2018. This compared to gross margins for Luobuma products, Chinese medicinal herbal products, and other agricultural products of 50.0%, 25.6%, and 35.3%, respectively, for the same period of last year.

Operating income

Selling expenses increased by $0.05 million, or 3.9%, to $1.23 million for the nine months ended March 31, 2018 from $1.19 million for the same period of last year, primarily due to the acquisition of a new subsidiary, Tianjin Tajite, in October 2017. The increase in selling and distribution expenses was also a result of increased promotion expenses as the Company enhanced its online sales promotions, partially offset by decreased rent expense of warehouse and salary expenses due to more effective cost control during the nine months ended March 31, 2018 compared to the same period of 2017. General and administrative expenses increased by $0.79 million, or 39.0%, to $2.82 million for the nine months ended March 31, 2018 from $2.03 million for the same period of last year. The increase in general and administrative expenses was primarily attributable to the incorporation and acquisition of new subsidiaries, Tiankunrunze in second quarter of fiscal year 2017, and Xinjiang Taihe and Tianjin Tajite in fiscal year 2018.  The increase in general and administrative expenses was also a result of increased professional service fees, such as attorney’s fees, consulting fees and auditing fees. As a result, total operating expenses increased by $0.84 million, or 26.0%, to $4.05 million for the nine months ended March 31, 2018 from $3.22 million for the same period of last year.

Operating income increased by $2.86 million, or 54.4%, to $8.11 million for the nine months ended March 31, 2018 from $5.25 million for the same period of last year. Operating margin was 23.0% for the nine months ended March 31, 2018, compared to 20.6% for the same period of last year.

Net income

Net income increased by $3.12 million, or 50.0%, to $9.35 million for the nine months ended March 31, 2018 from $6.23 million for the same period of last year. After the deduction of non-controlling interests, net income attributable to common shareholders for the nine months ended March 31, 2018 was $9.41 million, or $0.45 per basic and diluted share. This compared to net income attributable to common shareholders of $6.12 million, $0.30 per basic and diluted share, for the same period of last year.

Financial Condition

As of March 31, 2018, the Company had cash and cash equivalents of $28.43 million, compared to $23.15 million as of June 30, 2017. Net cash used in operating activities was $5.34 million for the nine months ended March 31, 2018, compared to net cash used in operating activities of $1.38 million for the same period of last year. Net cash used in investing activities was $0.90 million for the nine months ended March 31, 2018, compared to $1.69 million for the same period of last year. Net cash used in financing activities was $0.45 million for the nine months ended March 31, 2018, compared to net cash provided by financing activities of $5.60 million for the same period of last year.

About Shineco, Inc.

Incorporated in August 1997 and headquartered in Beijing, China, Shineco, Inc. (“Shineco” or the “Company”) is a Delaware holding company that uses its subsidiaries’ and variable interest entities’ vertically- and horizontally-integrated production, distribution and sales channels to provide health and well-being focused plant-based products in China. Utilizing modern engineering technologies and biotechnologies, Shineco produces, among other products, Chinese herbal medicines, organic agricultural produce and specialized textiles. For more information about the Company, please visit www.shinecobiotech.com.

Forward-Looking Statements

This press release contains information about Shineco’s view of its future expectations, plans and prospects that constitute forward-looking statements. Actual results may differ materially from historical results or those indicated by these forward-looking statements as a result of a variety of factors including, but not limited to, risks and uncertainties associated with its ability to raise additional funding, its ability to maintain and grow its business, variability of operating results, its ability to maintain and enhance its brand, its development and introduction of new products and services, the successful integration of acquired companies, technologies and assets into its portfolio of products and services, marketing and other business development initiatives, competition in the industry, general government regulation, economic conditions, dependence on key personnel, the ability to attract, hire and retain personnel who possess the technical skills and experience necessary to meet the requirements of its clients, and its ability to protect its intellectual property. Shineco encourages you to review other factors that may affect its future results in Shineco’s registration statement and in its other filings with the Securities and Exchange Commission.

For more information, please contact:

Tina Xiao
Ascent Investor Relations LLC
Phone: +1-917-609-0333
Email: tina.xiao@ascent-ir.com 

View original content:http://www.prnewswire.com/news-releases/shineco-inc-reports-third-quarter-of-2018-financial-results-300650566.html

Source: Lallemand Inc.

LONDON, May 16, 2018 /PRNewswire/ — The consumer robotics market is evolving rapidly and covers a wide array of products, from homecare systems to children’s toys to smart ‘humanoid’ robots that provide personal and social engagement. According to ABI Research, a market-foresight advisory firm providing strategic guidance on the most compelling transformative technologies, the entire consumer robotics market will reach 100 million shipments and US$23 billion in revenue by 2026.

Homecare robots are already the primary driver of revenue for the wider consumer robotics market. This trend is expected to increase, following a banner year of revenue and shipment growth from floor care market leader iRobot. From 2016 to 2017, iRobot’s yearly revenue jumped from US$2.93 billion to US$3.69 billion, a major increase on returns from previous years. While iRobot dominates the American and European markets, Chinese manufacturers such as Ecovacs are beginning to post comparable shipment figures, and long-term, Asia-Pacific (APAC) will closely match North America and Europe in market share for homecare robots.

“General improvement in global GDP growth and consumer confidence recovery, particularly in the U.S. market, have led to substantial revenue growth from market leaders, such as iRobot, Ecovacs, and Neato,” says Rian Whitton, Research Analyst at ABI Research. “In addition, niche segments, such as pool cleaning, have begun to expand in popularity. Israeli-centered market leader Maytronics has recently expanded into the American market and posting double-digit growth over a consistent time frame.”

By contrast, the toys and entertainment segment will decline in market share. Their share of shipments will decrease from 75% in 2014 to 47.1% in 2026 (still the largest segment), while their share of revenue will crater from 31.7% to 10% in the same period. The reason for this relative decline is in part a question of semantics. In this same period, personal/social robots are expected to increase their market share of revenue from virtually nothing to 21.3% in 2026.

“Over time, ABI expects these more sophisticated systems to colonize the traditional toys market and to replace rudimentary robotic toys with more sophisticated general-purpose smart devices. Mobile personal robots will resemble many of the higher-end entertainment robots in appearance, but will possess more advanced technologies, including cellular technology, Wi-Fi connectivity, and possibly even on-device machine learning,” concludes Whitton. There are several toys that could already fall under the definition of personal robots, such as WowWee’s Robosapien. A further example might be Anki’s Cozmo, an educational toy robot designed to teach coding principles to children.

These findings are from ABI Research’s Consumer Robotics report. This report is part of the company’s Robotics, Automation & Intelligent Systems research service, which includes research, data, and Executive Foresights. 

About ABI Research

ABI Research provides strategic guidance for visionaries needing market foresight on the most compelling transformative technologies, which reshape workforces, identify holes in a market, create new business models and drive new revenue streams. ABI’s own research visionaries take stances early on those technologies, publishing groundbreaking studies often years ahead of other technology advisory firms. ABI analysts deliver their conclusions and recommendations in easily and quickly absorbed formats to ensure proper context. Our analysts strategically guide visionaries to take action now and inspire their business to realize a bigger picture. For more information about ABI Research’s forecasting, consulting and teardown services, visionaries can contact us at +1.516.624.2500 in the Americas, +44.203.326.0140 in Europe, +65.6592.0290 in Asia-Pacific or visit www.abiresearch.com.

Logo – https://mma.prnewswire.com/media/276887/abi_research_logo.jpg

DARMSTADT, Germany, May 17, 2018 /PRNewswire/ —

Not intended for UK- or US-based media 

ASCO Abstract #
ERBITUX® (cetuximab): 3521, 3534, e15711; avelumab: 9507, 9537, 9090, 9008, 8563, 3057, 4544, e21531, e13603, e18932, e21623, e21620, e21544; tepotinib (c-Met kinase inhibitor): 9082, 9016; M6620 (ATR inhibitor): 2549, e21048; M3814 (DNA-PK): 2518 M7824 (TGF-ß trap/anti-PD-L1): 3007, 9017, 2566; M2698 (dual p70S6k/Akt inhibitor): 2584

• Two-year safety and efficacy data in mMCC for avelumab from pivotal JAVELIN Merkel 200 trial 
• Further data reinforcing commitment to precision medicine and position of ERBITUX^® (cetuximab) as a standard of care in mCRC 
• Early clinical activity in advanced NSCLC and HPV-associated cancers for investigational bifunctional immunotherapy, M7824 
• Encouraging interim analysis of Phase II data in NSCLC sub-population for c-Met inhibitor, tepotinib 
• Record number of abstracts accepted across oncology, immuno-oncology and DNA Damage Response (DDR)  

Merck, a leading science and technology company, today announced new data from a number of high priority clinical development programs across its oncology portfolio to be presented at this year’s American Society of Clinical Oncology Annual Meeting (ASCO), June 1-5, 2018, Chicago, IL. Abstracts representing seven therapeutic agents and eight tumor types will highlight Merck’s position as a key emerging player in oncology.

“This year’s data at ASCO demonstrate the potential of our pipeline to really deliver transformative advancements in cancer care,” said Luciano Rossetti, Executive Vice President, Head of Global Research & Development at the biopharma business of Merck. “With our strong commitment and focus on the areas we believe in most, Merck’s oncology and immuno-oncology pipeline is demonstrating significant potential in the near term with our later-stage priority programs and, in parallel, our early pipeline includes truly innovative programs that could make a real difference for patients.”

Data for the legacy brand ERBITUX^® continue to build on Merck’s heritage in oncology reinforcing its role as a standard of care in RAS wild-type metastatic colorectal cancer (mCRC), the standard of care in first-line recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN), and a standard of care for patients with locally advanced SCCHN (LA SCCHN), who may not be able to tolerate cisplatin-based regimens in full.

New data for avelumab* (BAVENCIO^®), which is being jointly developed and commercialized with Pfizer, include an oral presentation on two-year results from the pivotal JAVELIN Merkel 200 trial. These long-term results include data on avelumab’s duration of response and represent the first study to report long-term survival data for an immunotherapy in metastatic Merkel cell carcinoma (mMCC).

The company will also present further evidence for M7824, an investigational TGF-ß trap/anti-PD-L1 bi-functional immunotherapy fusion protein, from expansion cohorts of the ongoing M7824 Phase I clinical trial (NCT02517398) program. TGF-β, a cytokine released by cells (including tumor cells), suppresses anti-tumor immune responses through a vast number of mechanisms leading to uninhibited tumor growth and metastasis. These data include results in patients with human papillomavirus (HPV)-associated cancers (presented in collaboration with the National Cancer Institute) and data in patients with advanced non-small cell lung cancer (NSCLC). In second-line (2L) NSCLC, signs of clinical activity were seen across PD-L1 expression levels. At the recommended Phase II dose, a confirmed overall response rate (ORR) of 40.7% (11/27) was observed in PD-L1+ patients (>1%), and in patients with high PD-L1 expression (80%; Ab clone 73-10 [>80%=>50% with 22C3]), the ORR was 71.4% (5/7). These data signal the potential of M7824 and provide evidence that combining a transforming growth factor-β (TGF-β) trap with the anti-PD-L1 mechanism in one molecule may generate anti-tumor activity in these patient groups with significant medical need. Treatment with M7824 was well tolerated in both studies and safety data were consistent with that observed in the overall Phase I clinical program. No new safety signals were identified.

For tepotinib**, an investigational highly selective small molecule inhibitor of the c-Met receptor tyrosine kinase, new data to be presented include promising initial results from an ongoing Phase II VISION study providing further indication for the potential of tepotinib in patients living with advanced NSCLC harboring MET exon 14 skipping mutations. Alterations of the c-Met signaling pathway are found in various cancer types and correlate with aggressive tumor behavior and poor clinical prognosis. Based on investigator assessment of data from 15 patients in the study, 60% (9/15) had a confirmed partial response (PR) and 20% (3/15) had stable disease (SD). In addition, independent assessment of 13 patients demonstrated treatment with tepotinib led to a confirmed PR in 46.2% (6/13) and SD in 7.7% (1/13) of patients. In this study, the safety data are consistent with that observed in previous studies and confirm that treatment with tepotinib is well tolerated; no new safety signals were identified.

Tepotinib is an important part of Merck’s strategic focus on precision medicines and these results reinforce the company’s progress in delivering treatments to those patients more likely to benefit, in order to achieve the best possible outcomes. Both M7824 and tepotinib were discovered in-house at Merck.

Further pipeline updates include Phase I dose escalation data for the investigational DNA-dependent protein kinase (DNA-PK) inhibitor M3814, Phase I triplet therapy with ATR-inhibitor, M6620 +veliparib+cisplatin in advanced solid tumors, and Phase I data for M2698, a potent and selective dual inhibitor of p70S6K and AKT1/3 in the PAM pathway (PI3K/AKT/mTOR pathway). The PAM pathway regulates cell survival and growth and this pathway often displays unusual activity in many human cancers.

*Avelumab is under clinical investigation for treatment of NSCLC, metastatic urothelial carcinoma (mUC) and mesothelioma and has not been demonstrated to be safe and effective for these indications. There is no guarantee that avelumab will be approved for NSCLC, mUC and mesothelioma by any health authority worldwide.

**Tepotinib is the recommended International Nonproprietary Name (INN) for the c-Met kinase inhibitor (MSC2156119J). Tepotinib is currently under clinical investigation and not approved for any use anywhere in the world.

Tepotinib, M7824, M3814, M2698 and M6620 are under clinical investigation and have not been proven to be safe and effective. There is no guarantee any product will be approved in the sought-after indication by any health authority worldwide.

Notes to Editors 

Accepted Merck-supported key abstracts slated for presentation are listed below. In addition, a number of investigator-sponsored studies have been accepted (not listed).

All Merck Press Releases are distributed by e-mail at the same time they become available on the Merck Website. Please go to http://www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.

About Avelumab 

Avelumab is a human anti-programmed death ligand-1 (PD-L1) antibody. Avelumab has been shown in preclinical models to engage both the adaptive and innate immune functions. By blocking the interaction of PD-L1 with PD-1 receptors, avelumab has been shown to release the suppression of the T cell-mediated antitumor immune response in preclinical models. Avelumab has also been shown to induce NK cell-mediated direct tumor cell lysis via antibody-dependent cell-mediated cytotoxicity (ADCC) in vitro In November 2014, Merck and Pfizer announced a strategic alliance to co-develop and co-commercialize avelumab.

Approved Indications in the US 

The FDA granted accelerated approval for avelumab (BAVENCIO^®) for the treatment of (i) adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma (mMCC) and (ii) patients with locally advanced or metastatic urothelial carcinoma (mUC) who have disease progression during or following platinum-containing chemotherapy, or have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. These indications are approved under accelerated approval based on tumor response rate and duration of response. Continued approval for these indications may be contingent upon verification and description of clinical benefit in confirmatory trials.

Important Safety Information from the US FDA Approved Label 

The warnings and precautions for BAVENCIO include immune-mediated adverse reactions (such as pneumonitis, hepatitis, colitis, endocrinopathies, nephritis and renal dysfunction, and other adverse reactions), infusion-related reactions and embryo-fetal toxicity.

Common adverse reactions (reported in at least 20% of patients) in patients treated with BAVENCIO for mMCC and patients with locally advanced or mUC include fatigue, musculoskeletal pain, diarrhea, nausea, infusion-related reaction, peripheral edema, decreased appetite/hypophagia, urinary tract infection and rash.

About Erbitux^® (cetuximab)  

Erbitux^® is a highly active IgG1 monoclonal antibody targeting the epidermal growth factor receptor (EGFR). As a monoclonal antibody, the mode of action of Erbitux is distinct from standard non-selective chemotherapy treatments in that it specifically targets and binds to the EGFR. This binding inhibits the activation of the receptor and the subsequent signal-transduction pathway, which results in reducing both the invasion of normal tissues by tumor cells and the spread of tumors to new sites. It is also believed to inhibit the ability of tumor cells to repair the damage caused by chemotherapy and radiotherapy and to inhibit the formation of new blood vessels inside tumors, which appears to lead to an overall suppression of tumor growth. Erbitux also targets cytotoxic immune effector cells towards EGFR expressing tumor cells (antibody dependent cell-mediated cytotoxicity, ADCC).

The most commonly reported side effect with Erbitux is an acne-like skin rash. In approximately 5% of patients, hypersensitivity reactions may occur during treatment with Erbitux; about half of these reactions are severe.

Erbitux has already obtained market authorization in over 100 countries world-wide for the treatment of RAS wild-type metastatic colorectal cancer and for the treatment of squamous cell carcinoma of the head and neck (SCCHN). Merck licensed the right to market Erbitux, a registered trademark of ImClone LLC, outside the U.S. and Canada from ImClone LLC, a wholly-owned subsidiary of Eli Lilly and Company, in 1998.

About M3814 

M3814 is an investigational small-molecule which is thought to inhibit DNA-dependent protein kinase (DNA-PK). DNA-PK is a key enzyme for non-homologous end-joining (NHEJ), an important DNA double strand break (DSB) repair pathway. Clinical studies investigating combinations of M3814 with other commonly used DNA-damaging agents such as radiotherapy and chemotherapy are underway.

About M7824 

M7824 is an investigational bifunctional immunotherapy that is designed to bring together a TGF-β trap and ‘fuse’ it with the anti-PD-L1 mechanism. M7824 is designed to simultaneously block the two immunosuppressive pathways – targeting both pathways aims to control tumor growth by potentially restoring and enhancing anti-tumor responses. M7824 is currently in Phase I studies for solid tumors.

About M2698 

M2698 is an investigational small-molecule which is thought to inhibit p70S6K and Akt. Both targets are part of the PI3K/AKT/mTOR (PAM)pathway, which is often dysregulated in solid tumors.

About tepotinib 

Tepotinib (MSC2156119J) is an investigational small-molecule inhibitor of the c-Met receptor tyrosine kinase. Alterations of the c-Met signaling pathway are found in various cancer types and it is thought to correlate with aggressive tumor behavior and poor clinical prognosis.

About M6620 

M6620 (previously known as VX-970) is an investigational small-molecule thought to inhibit ataxia telangiectasia and Rad3-related protein (ATR). ATR is believed to be a key sensor for DNA damage, activating the DNA damage checkpoint and leading to cell cycle arrest. Inhibition of ATR could potentially enhance the efficacy of DNA-damaging agents, but is also being investigated as a monotherapy against tumors with high levels of replication stress induced by overexpression of oncogenes.

About Merck 

Merck is a leading science and technology company in healthcare, life science and performance materials. Almost 53,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2017, Merck generated sales of € 15.3 billion in 66 countries.

Founded in 1668, Merck is the world’s oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.

Contact: Gangolf Schrimpf, +49-6151-72-9591

Investor relations: +49-6151-72-3321

SEOUL, South Korea, May 16, 2018 /PRNewswire/ — South Korea has presented a new paradigm for stem cell therapy. GC Healthcare and Pharmicell have extended the application of CELLGRAM, a stem cell therapy product, for acute myocardial infarction, which is approved by KFDA, to erectile dysfunction. Its stem cell products were the world’s first commercialized stem cell therapy products in 2011.

Erectile dysfunction is one of the complications that is common and hard to treat after prostate cancer surgery. It is typically caused by a damage to the cavernous nerve running along the posterolateral aspects of the prostate. Stem cells stimulate the regeneration of damaged nerves, prevent cell apoptosis in the smooth muscles in the cavernous sinus, regenerate endothelial cells and help the formation of new blood vessels.

Since the completion of the clinical trial, Pharmicell has cooperated with GC Healthcare and started its service for those who have prostate cancer and come to South Korea to get treated.

GC Healthcare is one of the family groups of South Korea’s renowned pharmaceutical company, GC Pharma, and has focused on healthcare business for over 10 years. As Chinese patients’ demand for overseas treatment has increased, GC Pharma has established an international business department to recruit customers from abroad and has provided consulting services through the WeChat official account. GG Healthcare has been favorably commented upon for its satisfying services that have been provided for international customers over many years.

www.1888gc.com 

For Media Enquiries:

Medical Tourism Team
+82-2-2040-9149
mt@gchealthcare.com

Photo – https://photos.prnasia.com/prnh/20180515/2133558-1-QR

SHANGHAI, May 16, 2018 /PRNewswire/ — Medtec China, the leading medical device design and manufacturing exhibition in China, will take place 26-28 September 2018 in Shanghai. More than 400 exhibitors will showcase their latest offerings at Medtec China 2018, and more than 10,000 decision makers, purchasing staff, R&D engineers, product engineers and quality inspectors from medical device manufacturers will congregate at the show. This year’s event is going to showcase exhibits on medical raw material, components, tubing and extrusion, manufacturing equipment, contract manufacturing services, and regulatory consultant services in China.

Medtec China 2018 Visitor registration is available now, please click here to register at the official website or call +86 10-5730 6163 to help complete registration. Click here to discover why Medtec China is a must-attend show.

Medtec China 2017 one-minute video

Medtec China 2018 latest highlights:

Regulatory street debuts. This is a new launch zone at Medtec China 2018. With the exclusive support of Shanghai Pudong Medical Device Trade Association, consultant companies and keynote speakers from America, Europe and China will provide regulatory updates in China, the US and the EU in this zone.

The largest scale manufacturing equipment zone ever. International and domestic Chinese medical device manufacturing equipment suppliers from Switzerland, Singapore, Spain, Malaysia, Taiwan and mainland China will show up at Medtec China 2018 over an area of 2,000m², to provide a great experience for visitors.

5 reasons to attend Medtec China 2018

1. Access to more than 2,000 global suppliers of medical device design and manufacturing from Medtech World
2. Free access to advanced products/technologies/service for the medical design and manufacturing industry
3. Resolve key technical challenges and problems in the processes of medical product development and manufacturing
4. The opportunity to explore regulatory updates in China, the US and the EU
5. Access to market trends and forefront business opportunities

400 Medical design and manufacturing suppliers; 14 exhibit zones for better visiting experience

For a superior visiting experience, Medtec China has set up 14 exhibit zones: Medical Manufacturing Automation; Moulding & Manufacturing Equipment; Medical Components; Electronic Components; Surface Treatment; Full Service Contract Manufacturing; Ultra-Precision Machining; Packaging, Sterilization, Labeling; Design, Research & Development, Software Regulations; Testing, Metrology & Inspection Supplies; Materials & Adhesives; Materials, Components and Process; and Dressing Materials and Process.

2018 concurrent conferences help to access market trends

The MDiT Forum and Regulation Summit 2018 will discuss focused topics from four aspects: regulatory and policy; quality management; advanced technology; and market & investment.

Chinese Regulatory Updates and Compliance is always the most popular one. This year speakers are going to discuss the development prospects of the Chinese medical device industry, understanding of the medical device review and approval system by CFDA, and key points for the implementation of clinical trial quality management of medical devices in China.

The forum CFDA Flight Inspection and FDA Inspection, will invite global regulatory professionals and FDA officers to share their opinions on the implementation progress and information sharing of CFDA overseas inspections, and practical experiences of preparation and coping strategy for CFDA flight inspection and, from the view of medical device manufacturers, how to respond to FDA factory inspection programs and key points of reply to FDA483.

Next-Gen Design & New Technology can always easily attract engineers’ attention. Some advanced topics are going to be discussed at this year’s technology forum, for instance, getting the most of human factors engineering in medical device design, a case study on how to use disruptive design strategy in medical device design, and advancing medical devices by capturing the sense of visual and touch.

Efficient way to network with industry peers through rich onsite activities

Every year Medtec China organizes difference onsite activities to fulfil customer needs, Business Match Making, Exhibitor Theatre, Quality Focus, Exhibitor Seminars, MDEA global medical design excellence awards which always attract plenty of visitor to participant. To learn more about onsite activities please click here.

How to register:

1. Online Registration: Click the link to register on Medtec China official website: www.medtecchina.com
2. Telephone Registration: +86 10-5730 6163
3. Group Registration: If you are a group of more than five people visiting, please call us to simplify the process: +86 10-5730 6163

Media\Exhibit\Visit\Conference Contact:

Carina Li
UBM China
T: +86 10 5730 6163
E: carina.li@ubm.com 
Medtec China Organizing Committee

Photo – https://photos.prnasia.com/prnh/20180515/2133636-1-a
Photo – https://photos.prnasia.com/prnh/20180515/2133636-1-b
Photo – https://photos.prnasia.com/prnh/20180515/2133636-1-c

SHANGHAI, May 15, 2018 /PRNewswire/ — The 3rd Annual iACD World Congress, hosted by UBM Showstar (UBM Sino Expo), will be held at same time as DenTech China 2018 from Oct 31 to Nov 2 at Shanghai World Expo Exhibition and Convention Center. The International Academy of Contemporary Dentistry (iACD) is the first professional dental association in the world with the mission of providing culturally specific services from bilingual and bicultural Asian dental professionals. The iACD brings together researchers, practitioners, and industry professionals committed to advancing oral health among Asia-Pacific countries and throughout the world. The mission at iACD is to provide a multidisciplinary oral health education platform for dentists with the desire to better the quality of life of their patients by improving both their oral care and their long-term physical health. Please visit http://www.dentech.com.cn/en-us/index for more information about this congress.

With 2016 in Hong Kong and 2017 in New York, the Annual iACD Congress has successfully held two editions. On the theme of Innovative Team Approaches to Comprehensive Dentistry, the 3rd Annual iACD Congress will be held at Shanghai World Expo Exhibition and Convention Center in October 2018. This highly anticipated platform for the dental industry includes an international lineup of experts including Dr. Jon B. Suzuki, Dr. Steve G.F. Shen, Dr. Stephen Wallace, Dr. Shohei Kasugai, Dr. Charles J. Goodacre, Dr. Su Yucheng, Dr. Hideo Kawahara and Dr. Paul P Chang, please visit http://www.dentech.com.cn/en-us/Speaker-Profiles for more information on guest speakers.

iACD recognizes the importance of facilitating the flow of ideas in a scientifically, linguistically as well as culturally inclusive manner. Through providing professional multilingual resources in Asia-Pacific where academics and practitioners can present their work in a contextualized setting. 16 popular featured topics including “Risk management when operating in the posterior mandible”, “Interdisciplinary management of Complex Implant Treatment”, “New strategy for bone regenerating: Respecting the healing ability of the body“, etc. will be presented by over 20 famous professional speakers at this congress. For more information on featured topics, please visit http://www.dentech.com.cn/en-us/The-3rd-Annual-iACD-Congress.

2018 iACD World Congress also provides programs, presentations and topics on dental hygienist. Dental hygienists are oral health professionals who are responsible for preventing and treating oral diseases. All dental hygienists must be licensed, which requires graduating from a college or university dental hygienist program and passing a written national board examination and state clinical examination. They are extremely important to the whole dental industry.

Photo – https://photos.prnasia.com/prnh/20180502/2121832-1-a
Photo – https://photos.prnasia.com/prnh/20180502/2121832-1-c
Logo – https://photos.prnasia.com/prnh/20180502/2121832-1-b

HONG KONG, May 15, 2018 /PRNewswire/ — The Chairman of Cedrus Investments (“Cedrus”), Mr. Rani Jarkas, is invited to speak at the 121 Tech Investment conference to be held on 13^th – 14^thJune 2018 in Hong Kong.  At this event, senior executives from innovative industries, including life sciences and technology, and leading investors will discuss with other elites their unique observations and enlightening insights of the current market dynamics as well as prospects on future trends, with a focus on the most cutting-edge areas, including block-chain, smart cities and personalized medicines.       

Cedrus is among the leading experts and a longtime investor in life sciences, having an unparalleled advisory board in-house expertise consisting of world-renowned physicians and experts. Mr. Jarkas will join a panel discussion, sharing not only his knowledge and insights into some of the most innovative areas in life sciences such as gene editing, but also his experience in the active involvement in the rapidly-changing Chinese life sciences industry where investments in innovations and cross-border transactions are of top priority.  

Mr. Jarkas said, “Life sciences has long been the most important strategic focus of Cedrus in particular in the Greater China region, and we have been engaging in this industry for over two decades. Our success in establishing a unique and multi-dimensional global network, comprising of pundits with deep industry experience and expertise, as well as our good relationships with local governments in China has resulted in a win-win situation for both our valuable global clientele and business partners in and outside of China. While Chinese investors and strategic partners are vigorously pursuing overseas cutting-edge technologies, western life sciences companies are keen to capture the business opportunities presented by China, the world’s second-largest pharmaceutical market. I am glad to be invited to participate in a panel discussion where I have the chance to exchange my thoughts with a few industry leaders in an effort to jointly explore and identify impactful life sciences investments that will ultimately become the new growth engines of the industry.”

About Cedrus Investments

Cedrus Investments is a global boutique investment firm that offers expertise in private wealth management, asset management and financial advisory services to a clientele of leading institutional investors, corporations, family offices and high net worth individuals around the world.

For further information about Cedrus Investments, please visit www.cedrusinvestments.com.

Media Enquiry:
Cedrus Investments Ltd.
Amy Sin
+852-3519-2828
information@cedrusinvestments.com

Logo – http://photos.prnasia.com/prnh/20150930/8521506461LOGO

CHENGDU, China, May 14, 2018 /PRNewswire/ — Oracle Health Sciences today announced that Sichuan Kelun Pharmaceutical Research Institute Co., Ltd (“Kelun”) has implemented Oracle Health Sciences Clinical One Randomization and Supplies Management Cloud Service to fully automate the set up and management of its multi-site, double blind colorectal cancer study. 

The China Food and Drug Administration (CFDA) has been driving reforms to improve the quality of drugs and to encourage innovation in the development of new drugs and medical devices. Kelun Pharmaceutical has been successfully conducting generics drug research since 1996 but recently launched its first, new oncology drug study. As with any new clinical trial, there is tremendous time and resources required to set up a new study including trial design and validation which can take weeks to months. ORS enables coordinators to quickly add patients to a trial, collect screening information and ensure eligibility for randomization in record time. In an effort to set up their own trial and eliminate manual, repetitive data entry, Kelun implemented Clinical One Randomization and Supplies Management Cloud Service.  

“We needed an established, standards-based cloud system to simplify the drug supply management process, and we have already determined we made a great choice by selecting Oracle’s Clinical One Randomization and Supplies Management. Within 29 days, we were fully implemented and are now in phase III of our oncology trial,” said Xiaoping Zhang, VP of Biostatistics and Data Management, Clinical Research Hub.

With Clinical One Randomization and Supplies Management, Kelun has been able to manage its trial supply and randomization more effectively and efficiently and has enabled its CRO partner and service providers, including its supply shipping specialist vendor, to automate their processes by leveraging Oracle Health Science’s cloud-based system. In addition to simplifying the drug supply management process, ORS has provided Kelun with role-based analytics to track and manage supply status in real time.

“Our eClinical platform, Clinical One and randomization and supplies management capability was designed for pharmaceutical and biopharma companies of all sizes, across all treatment areas and for all phases of research and development. We are excited to see Kelun leveraging technology to speed the setup and management of their trial and are hopeful that this oncology therapy will make it to market,” said Steve Rosenberg, general manager and senior vice president, Oracle Health Sciences.

Additional Resources

About Oracle
The Oracle Cloud offers complete SaaS application suites for ERP, HCM and CX, plus best-in-class database Platform as a Service (PaaS) and Infrastructure as a Service (IaaS) from data centers throughout the Americas, Europe and Asia. For more information about Oracle (NYSE:ORCL), please visit us at oracle.com

Trademarks
Oracle and Java are registered trademarks of Oracle and/or its affiliates. Other names may be trademarks of their respective owners.

Logo- https://mma.prnewswire.com/media/467598/Oracle_Logo.jpg

SINGAPORE, May 14, 2018 /PRNewswire/ — As a company whose purpose is to make the world healthier and happier, premier global nutrition company, Herbalife Nutrition, has wrapped up Extravaganza, its annual education and training event for the Southeast Asia member community. The three-day event, at the Singapore Expo, began May 11 with the Herbalife Nutrition leadership team rallying more than 11,000 independent members to be the difference in each of their local communities by inspiring them to take steps towards positive nutrition for healthier, happier lives.

“In the face of the global megatrends of high obesity rates, a rapidly aging population, increasing public healthcare costs, and a rise in entrepreneurial interests, we believe we can play an even greater role in providing practical solutions to help build a better future for us all,” said Stephen Conchie, senior vice president and managing director, Herbalife Nutrition Asia Pacific. “Extravaganza is the perfect platform to gather our members and equip them with the knowledge to build a healthier Southeast Asia.”  

Herbalife Nutrition’s members are trained and equipped to be at the frontline of nutrition conversations, providing personalized nutrition and fitness services to consumers. Through this personalized, face-to-face approach, members are able to customize specific nutrition programs for each individual, to meet consumers’ nutrition needs and spur them on towards their health and wellness goals.

“Our products, along with educated and trained members, provide consumers with an effective personalized solution to their nutrition and wellness goals,” Conchie added.

During the three-day event, Herbalife Nutrition’s member base had the opportunity to hear from nutrition experts and Rich Goudis, the CEO of Herbalife Nutrition, who delivered an inspiring keynote message that instilled a sense of purpose into the member community to empower them with the vision and ability to make the world a happier and healthier one.

Conchie also outlined his vision for the Southeast Asia member community to make a real difference in their respective communities by providing the right motivation and support to empower the people around them to make positive nutrition and lifestyle changes.

About Herbalife Nutrition

Herbalife Nutrition is a global nutrition company whose purpose is to make the world healthier and happier. The Company has been on a mission for nutrition – changing people’s lives with great nutrition products and programs – since 1980. Together with our Herbalife Nutrition independent members, we are committed to providing solutions to the worldwide problems of poor nutrition and obesity, an aging population, skyrocketing public healthcare costs and a rise in entrepreneurs of all ages. Herbalife Nutrition offers high-quality, science-backed products, most of which are produced in Company-operated facilities, one-on-one coaching with an Herbalife Nutrition independent member, and a supportive community approach that inspires customers to embrace a healthier, more active lifestyle.

Herbalife Nutrition’s targeted nutrition, weight-management, energy and fitness and personal care products are available exclusively to and through its independent members in more than 90 countries. Through its corporate social responsibility efforts, Herbalife Nutrition supports the Herbalife Family Foundation (HFF) and its Casa Herbalife programs to help bring good nutrition to children in need. Herbalife Nutrition is also proud to sponsor more than 190 world-class athletes, teams and events around the globe, including Cristiano Ronaldo, the LA Galaxy, and numerous Olympic teams.

Herbalife Nutrition has over 8,000 employees worldwide, and its shares are traded on the New York Stock Exchange (NYSE: HLF) with net sales of approximately US$4.4 billion in 2017. To learn more, visit Herbalife.com or IAmHerbalife.com.

Media Enquiries:

Daliea Mohamad-Liauw
VP, Corporate Communications, Herbalife Nutrition Asia Pacific
DID: +852–3589–2643
Email: dalieal@herbalife.com

Photo – https://photos.prnasia.com/prnh/20180514/2131928-1